ResultsIQ

ResultsIQ › Latest results › CARE Ratings Limited

CARE Ratings Limited Q1 FY26 results deck summary

NSE: CARERATING · BSE: 534804

Results deck of 5 Aug 2025, summarised by AI from the filing.

Standalone PAT ₹29.1 cr with 32% margin; consolidated PAT ₹26.5 cr with 25% margin.

Key takeaways

  1. Profitability Standalone PAT ₹29.1 cr with 32% margin; consolidated PAT ₹26.5 cr with 25% margin.
  2. Segment mix Non-ratings business contribution to consolidated revenue increased to 12%.
  3. Ratings growth Ratings business revenue ₹82.9 cr, up 18% YoY.
  4. Risk Global economic uncertainties pose headwinds for a meaningful revival in private capex.

Original filing on BSE

CARE Ratings Limited Q1 FY27 results

As filed: Revenue ₹112 cr (+19% year on year), EBITDA ₹34.6 cr (+28% year on year), PAT ₹33.0 cr (+22% year on year), EBITDA margin 31.0% (+228 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹131 cr (+19% year on year), EBITDA ₹60.8 cr (+27% year on year), PAT ₹53.5 cr (+24% year on year), EBITDA margin 46.5% (+286 bps). Score 47 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 286 bps year on year. Revenue rose ₹20.7 cr on a year ago, more than the ₹20.0 cr it added the year before. Share price after the results: +1.1% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹112 cr (+17% year on year), EBITDA ₹40.3 cr (+30% year on year), PAT ₹36.5 cr (+31% year on year), EBITDA margin 36.0% (+369 bps). Score 53 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 369 bps year on year. Other income 27% of PBT. Revenue fell 18% from last quarter. Revenue rose ₹16.1 cr on a year ago, against ₹17.0 cr the year before. Share price after the results: −1.1% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹136 cr (+16% year on year), EBITDA ₹68.0 cr (+24% year on year), PAT ₹57.0 cr (+21% year on year), EBITDA margin 50.0% (+299 bps). Score 47 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 299 bps year on year. Revenue rose ₹19.0 cr on a year ago, against ₹21.0 cr the year before. Share price after the results: +1.4% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹94.0 cr (+19% year on year), EBITDA ₹27.0 cr (+29% year on year), PAT ₹27.0 cr (+29% year on year), EBITDA margin 28.7% (+214 bps). Score 59 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 214 bps year on year. Other income 38% of PBT. Revenue fell 15% from last quarter. Revenue rose ₹15.0 cr on a year ago, more than the ₹13.0 cr it added the year before. Share price after the results: −6.6% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹110 cr (+22% year on year), EBITDA ₹48.0 cr (+66% year on year), PAT ₹43.0 cr (+72% year on year), EBITDA margin 43.6% (+1,000 bps). Score 78 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 1000 bps year on year. Other income 25% of PBT. Revenue rose ₹20.0 cr on a year ago, more than the ₹12.0 cr it added the year before. Share price after the results: +44.2% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹96.0 cr (+22% year on year), EBITDA ₹31.0 cr (+35% year on year), PAT ₹28.0 cr (+17% year on year), EBITDA margin 32.3% (+318 bps). Score 45 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 318 bps year on year. Other income 31% of PBT. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue fell 18% from last quarter.
  • Q2 FY25: Revenue ₹117 cr (+22% year on year), EBITDA ₹55.0 cr (+31% year on year), PAT ₹47.0 cr (+31% year on year), EBITDA margin 47.0% (+326 bps). Score 77 of 100, Above trend. EBITDA margin rose 326 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

CARE Ratings Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.